Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome
01 mars 2021 12h21 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered...
Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer
09 févr. 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharma.China National Medical Products Administration (NMPA) grants breakthrough Therapy...
Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic
08 févr. 2021 15h21 HE
|
Sorrento Therapeutics, Inc.
The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic Clinical studies utilizing the ADNAB™ platform are ongoing at the Mayo Clinic; and are evaluating multiple...
Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells
31 janv. 2021 17h28 HE
|
Sorrento Therapeutics, Inc.
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC starting Monday (January 25, 2021) and discharged last Friday (January...
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
26 janv. 2021 19h09 HE
|
Sorrento Therapeutics, Inc.
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse events noted for any patient treated to date SAN DIEGO, Jan. 26, 2021 ...
Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein
19 janv. 2021 17h06 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutation...
Dr. Henry Ji to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 20, 2021
19 janv. 2021 02h06 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming...
Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference
10 janv. 2021 17h58 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming...
Sorrento Announces the Submission of a Marketing Authorization Application to COFEPRIS (Mexico) for COVI-STIX™ Rapid Detection Test of SARS-CoV-2 Viral Antigen
30 déc. 2020 12h48 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that a Marketing Authorization Application has been submitted by its agents in...
Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX™ Rapid Test for the Detection of SARS-CoV-2 Viral Antigen
22 déc. 2020 18h59 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that an Emergency Use Authorization (EUA) Application has been submitted to the US...